Most cancers can be cured by surgery in their early stages, when the tumors are localized. What makes ovarian cancer so deadly is that distinct symptoms seldom develop until the cancer spreads outside the ovaries. The major goal for screening, therefore, is to detect ovarian cancer before it metastasizes. Researchers have developed a new “liquid biopsy” test that they hope has the capacity to identify the presence of relatively early cancers. In an early assessment, this test detected 98% of ovarian cancers in a test group of patients who had stage II or greater disease that had not yet metastasized.
What does the new study showing a link between low-dose hormonal contraceptives and breast cancer really tell us in practical terms? First, that the risk has not gone away with the introduction of pills delivering newer and lower formulations, and second, that the risk is significant at the population level but tiny at the individual level. It is important to unpack the study’s findings to really put them into perspective.
Coming in early 2018 is a new one-dose oral treatment for bacterial vaginosis (BV). The drug’s effectiveness is similar to that of the metronidazole, a treatment currently recommended by the Centers for Disease Control and Prevention, but with an ease of use that may enhance adherence to treatment regimen.
The “Contraceptive Technology” conferences will help you synthesize the data and translate the evidence into clinical “pearls” you can put directly into practice. With an array of Preconferences delving into selected specialty areas of interest, plenary sessions focusing on the “hottest” topics, a thought-provoking luncheon presentation, and 30 dynamic, interactive Concurrent Sessions, including hands-on workshops…this conference is certain to improve your clinical practice and expand your network of colleagues. Read more